Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: A case for looking beyond serotonin

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 4, 2007, Pages 959-960

  Zurowski, Bartosz ^a   Wahl, Karina ^b   Hohagen, Fritz ^b   Kordon, Andreas ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADULT; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; NEUROLOGIC DISEASE; OBSESSIVE COMPULSIVE DISORDER; RATING SCALE; REMISSION; SIDE EFFECT;

ADULT; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; REMISSION INDUCTION; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 34247517337     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.12.023     Document Type: Letter

References (15)

1. Arnold P.D., Sicard T., Burroughs E., Richter M.A., and Kennedy J.L. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63 7 (2006) 769-776
2. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7 2 (2006) 137-151
3. Bubar M.J., McMahon L.R., De Deurwaerdere P., Spampinato U., and Cunningham K.A. Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens. Neuropharmacology 44 3 (2003) 342-353
4. Campbell K.M., de Lecea L., Severynse D.M., Caron M.G., McGrath M.J., Sparber S.B., et al. OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons. J Neurosci 19 12 (1999) 5044-5053
5. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58 5 (2005) 424-428
6. Damsa C., Bumb A., Bianchi-Demicheli F., Vidailhet P., Sterck R., Andreoli A., et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 65 8 (2004) 1064-1068
7. Denys D., Zohar J., and Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65 Suppl 14 (2004) 11-78
8. Herges S., and Taylor D.A. Involvement of 5-HT(3) receptors in the nucleus accumbens in the potentiation of cocaine-induced behaviours in the rat. Br J Pharmacol 131 7 (2000) 1294-1302
9. Keuneman R.J., Pokos V., Weerasundera R., and Castle D.J. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 39 5 (2005) 336-343
10. Kordon A., Kahl K.G., Broocks A., Voderholzer U., Rasche-Rauchle H., and Hohagen F. Clinical outcome in patients with obsessive-compulsive disorder after discontinuation of SRI treatment: results from a two-year follow-up. Eur Arch Psychiatry Clin Neurosci 255 1 (2005) 48-50
11. Lammers C.H., Diaz J., Schwartz J.C., and Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5 4 (2000) 378-388
12. Moore G.J., MacMaster F.P., Stewart C., and Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psych 37 6 (1998) 663-667
13. Shioda K., Nisijima K., Yoshino T., and Kato S. Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuro-Psychopharmacol Biol Psychiatry 28 4 (2004) 633-640
14. Tass P.A., Klosterkotter J., Schneider F., Lenartz D., Koulousakis A., and Sturm V. Obsessive-compulsive disorder: development of demand-controlled deep brain stimulation with methods from stochastic phase resetting. Neuropsychopharmacology 28 Suppl 1 (2003) S27-S34
15. Tollefson G.D., Birkett M., Koran L., and Genduso L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55 (1994) 69-76 [Suppl]